CellaVision (Sweden) Performance
| CEVI Stock | SEK 218.50 5.50 2.46% |
The firm shows a Beta (market volatility) of 0.64, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CellaVision's returns are expected to increase less than the market. However, during the bear market, the loss of holding CellaVision is expected to be smaller as well. At this point, CellaVision AB has a negative expected return of -0.28%. Please make sure to confirm CellaVision's jensen alpha, treynor ratio, value at risk, as well as the relationship between the total risk alpha and maximum drawdown , to decide if CellaVision AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days CellaVision AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 102.3 M | |
| Total Cashflows From Investing Activities | -84.3 M |
CellaVision |
CellaVision Relative Risk vs. Return Landscape
If you would invest 26,600 in CellaVision AB on August 31, 2024 and sell it today you would lose (4,750) from holding CellaVision AB or give up 17.86% of portfolio value over 90 days. CellaVision AB is generating negative expected returns and assumes 2.3287% volatility on return distribution over the 90 days horizon. Simply put, 20% of stocks are less volatile than CellaVision, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
CellaVision Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CellaVision's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CellaVision AB, and traders can use it to determine the average amount a CellaVision's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1183
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CEVI |
Estimated Market Risk
| 2.33 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.28 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average CellaVision is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CellaVision by adding CellaVision to a well-diversified portfolio.
CellaVision Fundamentals Growth
CellaVision Stock prices reflect investors' perceptions of the future prospects and financial health of CellaVision, and CellaVision fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CellaVision Stock performance.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 6.21 B | |||
| Shares Outstanding | 23.85 M | |||
| Price To Earning | 90.85 X | |||
| Price To Book | 10.18 X | |||
| Price To Sales | 9.60 X | |||
| Revenue | 565.55 M | |||
| EBITDA | 193.6 M | |||
| Cash And Equivalents | 190.2 M | |||
| Cash Per Share | 7.97 X | |||
| Total Debt | 95.84 M | |||
| Debt To Equity | 9.10 % | |||
| Book Value Per Share | 26.90 X | |||
| Cash Flow From Operations | 159.72 M | |||
| Earnings Per Share | 5.27 X | |||
| Total Asset | 825.21 M | |||
| Current Asset | 195 M | |||
| Current Liabilities | 40 M | |||
About CellaVision Performance
Assessing CellaVision's fundamental ratios provides investors with valuable insights into CellaVision's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the CellaVision is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
CellaVision AB develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden and internationally. CellaVision AB was founded in 1994 and is headquartered in Lund, Sweden. CellaVision operates under High Precision And Instrumentation Products classification in Sweden and is traded on Stockholm Stock Exchange. It employs 129 people.Things to note about CellaVision AB performance evaluation
Checking the ongoing alerts about CellaVision for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CellaVision AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CellaVision AB generated a negative expected return over the last 90 days | |
| About 38.0% of the company shares are held by company insiders |
- Analyzing CellaVision's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CellaVision's stock is overvalued or undervalued compared to its peers.
- Examining CellaVision's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CellaVision's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CellaVision's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CellaVision's stock. These opinions can provide insight into CellaVision's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for CellaVision Stock Analysis
When running CellaVision's price analysis, check to measure CellaVision's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CellaVision is operating at the current time. Most of CellaVision's value examination focuses on studying past and present price action to predict the probability of CellaVision's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CellaVision's price. Additionally, you may evaluate how the addition of CellaVision to your portfolios can decrease your overall portfolio volatility.